HIV/HCV Coinfection in Spain: Prevalence and Patient Characteristics
Juan Berenguer(Instituto de Salud Carlos III), Juan González‐García(Hospital Universitario La Paz), Inmaculada Jarrín(Instituto de Salud Carlos III), Manuel Crespo, Peré Domingo(Hospital de Sant Pau), Antonio Rivero(University of Southern California), José Antonio Iribarren(Biogipuzkoa Health Research Institute), María Jesús Téllez(Hospital Clínico San Carlos), Carmen Quereda(Instituto Cajal), M.J. Núñez(Hospital Universitario La Paz)
Cited by 1
Related Papers
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
|Clinical Microbiology and Infection|2020|423
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342
Autologous hematopoietic stem cell transplantation in multiple sclerosis
|Neurology|2015|247
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143